Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Eylea, used to treat age-related wet macular degeneration, is contending with its first-ever clearance of biosimilar versions from Indian drugmaker Biocon and collaborative efforts of Samsung Bioepis and Biogen.
In its first-to-file application for Yesafili, Biocon Biologics announced their US FDA approval for the vascular endothelial growth factor inhibitor, with indications for several different ophthalmology conditions. The product is intended to treat neovascular age-related macular degeneration, visual impairment from macular oedema secondary to retinal vein occlusion, visual impairment from diabetic macular oedema, and visual impairment from myopic choroidal neovascularisation.
The US FDA’s approval of Yesafili marks an opportunity for expansion for Bion Biologics into the US ophthalmology market after approvals in Europe and the UK. Yesafili was the first biosimilar for Eylea to be accepted in the UK. A launch date in Canada is expected to be no later than July 2025. “The FDA approval of Yesafili as the first interchangeable biological product to Eylea is a significant milestone for Biocon Biologics, marking our entry into ophthalmology, a new therapeutic are in the United States,” commented Shreehas Tambe, CEO & Managing Director of Biocon Biologics.
Regeneron has previously taken companies to court over Eylea biosimilars, with lawsuits filed against companies like Amgen and Biocon. In the US market, Regeneron brought in US$5.72 billion in Eylea sales in 2023. The pressure is mounting for the pharmaceutical company as more biosimilar threats loom.
Matt Erick, Chief Commercial Officer of Advanced Markets at Biocon Biologics, stated “Biosimilars are crucial for making healthcare more affordable and accessible. Yesafili will offer ophthalmologists an important new option for patients impacted by macular degeneration and diabetic retinopathy, from a company with a long history of delivering high-quality, science-driven medicines, solely focused on the development and commercialisation of biosimilars.”
Sources:
1. Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions [Accessed May 22, 2024] https://www.deccanherald.com/business/biocon-biologics-secures-usfda-approval-for-biosimilar-product-to-treat-ophthalmology-conditions-3031832
2. Biocon Biologics obtains US FDA approval for biosimilar afilbercept for Yesafili. Enters US ophthalmology market [Accessed May 22, 2024] https://www.biocon.com/biocon-biologics-obtains-u-s-fda-approval-for-biosimilar-aflibercept-for-yesafili-enters-u-s-ophthalmology-market/
3. US FDA approves two biosimilars for blockbuster eye drug Eylea [Accessed May 22, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biocon-units-biosimilar-blockbuster-eye-drug-eylea-2024-05-20/
Related News
-
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance